Oct 28, 2016, 10:09 AM
The first application for this technology is FSHD disease modelling and drug discovery.
Oct 27, 2016, 10:00 AM
Webcast to be held Oct 28, 2016 at 10:00 a.m. EDT with Dr. Statland. Archive available on website.
Oct 26, 2016, 9:55 AM
A proposal to study the histopathological features of muscle in a large biobank from FSHD patients and their first degree family members.
Oct 25, 2016, 9:51 AM
Development of an in vitro model of FSHD innate immunity.
Oct 6, 2016, 9:46 AM
aTyr Pharma, a company engaged in the discovery and development of therapeutics to address severe rare diseases, is currently conducting two trials of Resolaris (ATYR1940) in patients with rare myopathies with an immune component.